Mimetogen, a Montréal pharmaceutical company, has granted Bausch + Lomb an option to license MIM-D3, a treatment for dry-eye syndrome.

 

Without revealing the exact amount, Mimetogen’s CFO, François Mongrain, did state that the agreement would give the firm access to “millions of dollars,” that will be invested in the upcoming steps involved in bringing MIM-D3 to market.

 

The next step is a Phase-III study with 400 individuals at an estimated cost of $15 million. If the results are positive, Bausch + Lomb will have the option of acquiring an exclusive license to distribute the product worldwide. Bausch + Lomb will underwrite all the costs associated with the Phase-III study as well as all those associated with filing licensing submissions with regulatory authorities, in addition to paying development milestones and royalties to Mimetogen.

 

Mimetogen is a Montréal firm founded on the work of Uri Saragov, a researcher affiliated with McGill University who, in the early 2000s, created a class of molecules capable of mimicking the action of the nerve growth factor (NGF).

 

Source:

http://affaires.lapresse.ca/economie/quebec/201307/19/01-4672253-bausch-lomb-mise-sur-un-produit-mis-au-point-au-quebec.php

Essilor International announced today that it has signed an agreement to acquire the 51% stake in Transitions Optical owned by PPG. The French giant already had a 49% stake in Transitions.

 

Under the agreement, Essilor will also acquire Intercast, a sun lens manufacturer based in Parma, Italy. The transaction, which is expected to close during the first half of 2014, will cost Essilor $1.73 billion, as well as a deferred payment of $125 million dollars over five years.  

 

Essilor and PPG have jointly developed Transitions Optical since it was founded 23 years ago. “We look forward to a continued strong relationship with PPG as they will be providing ongoing research and development services and optical dyes to Transitions Optical under multi-year agreements with Essilor,” said President of Transitions Optical, Dave Cole.

 

Hubert Sagnières, Essilor’s Chairman and CEO, said that the acquisition of Transitions Optical is fully aligned with Essilor’s strategy. The integration process should be smooth due to the strong ties already existing between the two entities. “It will enable us to boost expansion in the photochromic segment, which is growing twice as fast as the optical industry, notably in Asia, Latin America and Europe.”

 

Sources : http://www.essilor.com/en/Press/News/Documents/2013/CP_ACCORD%20TOI%2029%20juillet_A.pdf

http://www.bfmtv.com/economie/essilor-acquiert-transitions-optical-leader-mondial-verres-photochromiques-569392.html

 

In the 1970s, the American television series “The Six Million Dollar Man” chronicled the adventures of Steve Austin, a hero with a bionic eye. Today, the first commercial bionic eye is available on the market.

 

Of course, the Argus II bionic eye implant does not let the blind see at extraordinary distances. In fact, it does not entirely restore sight, but it does help those suffering from retinitis pigmentosis recover partial vision. Argus II is a retinal implant that operates with external glasses equipped with a tiny camera. The camera records black and white images with a 60-pixel resolution. The data is then sent to a radio receptor in the Argus II device, activating microelectrodes, which relay electric signals to the optic nerve. The message is then sent to the brain.

 

Vision is in black and white, and the level of visual acuity is 20/1,260. The implant needs a functional optic nerve to accomplish its task, which makes it inoperable in AMD or glaucoma cases.

Source: http://www.bulletins-electroniques.com/actualites/73218.htm 

 

 

The firm GlobalData predicts that the market value of drugs for dry eye syndrome will triple over the next 10 years.

 

According to GlobalData, this growth will be fueled by the condition’s increasing prevalence, the arrival of new drugs, and the marketing of existing drugs in new territories. The firm gives the examples of Restasis (Allergan), very popular in the U.S., which will be launched in Europe by 2014, and Diquas (Santen Pharmaceuticals), available in Japan and Korea, which will soon be launched in China. The market could also see the arrival of new types of drugs, different from the current eye drops.

 

Drug sales in the U.S. presently account for 63% of the market share. GlobalData predicts that this percentage will drop to 47% in 2022, while the EU’s market shares will grow from 19% to 41%. The firm estimates that sales across the U.S., France, Germany, Italy, Spain, UK, Japan, China, and India will grow from $1.6 billion in 2012 to $5.5 billion in 2022, at an average annual growth rate of 12.8%.

Source: http://eyewiretoday.com/view.asp?20130613-dry_eye_syndrome_treatment_market_to_grow_by_nearly_4_billion_in_the_next_decade_says_globaldata

For the first time, a drug has a real positive impact on patients with metastatic uveal melanoma, a disease often qualified as “untreatable.”

 

The good news came from Memorial Sloan-Kettering Cancer Center, whose research results were presented at the 49th annual meeting of the American Society of Clinical Oncology. Researchers found that progression-free survival in patients treated with selumetinib was nearly 16 weeks, and half of these patients experienced tumour shrinkage, with 15% achieving major shrinkage.

 

In comparison, patients treated with temozolomide, the standard chemotherapy, had seven weeks of progression-free survival and no tumour shrinkage. Selumetinib also lengthened overall survival to 10.8 months versus 9.4 months with temozolomide.

 

“This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced uveal melanoma patients,” said lead author Richard D. Carvajal.

Source: http://www.mskcc.org/pressroom/press/new-therapy-shown-improve-progression-free-survival-and-shrink-tumors-rare-first-time